<DOC>
	<DOCNO>NCT02217501</DOCNO>
	<brief_summary>The purpose study evaluate whether clopidogrel 75 mg daily background aspirin 75-100 mg/d clinically indicate duration additional 12 month lead increase rate primary patency , limb salvage , non-fatal myocardial infarction ( MI ) , ischemic stroke , survival , patient receive endovascular treatment PAD end study treatment .</brief_summary>
	<brief_title>Antiplatelet Strategy Peripheral Arterial Interventions Revascularization Lower Extremities</brief_title>
	<detailed_description>Peripheral arterial disease ( PAD ) extremely prevalent worldwide affect 206 million people . Over 36 million patient PAD estimate present United States . Percutaneous revascularization therapy evolve dramatically , yet long-term success therapy remain modest morbidity mortality associate PAD remain high , 30 % mortality risk 5 year . Nearly , 3.2 million endovascular procedure perform annually . Though , exceed interventional procedure perform coronary artery disease ( CAD ) , current PAD guideline silent regard need optimal duration antiplatelet therapy ( APT ) patient follow endovascular procedure claudication critical limb ischemia ( CLI ) . The lack data clinical study far great impediment formulation guideline recommendation critically need provider patient alike , especially give current limited durability lower extremity endovascular procedure . The objective trial evaluate whether clopidogrel 75 mg QD background ASA 75-100 mg/d clinically indicate duration additional 12 month lead increase rate primary patency , limb salvage , non-fatal myocardial infarction ( MI ) , ischemic stroke , survival , patient receive endovascular treatment PAD end study treatment . The investigator hypothesize dual antiplatelet therapy ( DAPT ) ASA clopidogrel administer additional 12 month follow iliac , femoropopliteal knee endovascular intervention improve primary patency , limb salvage , freedom ischemic stroke survival , patient symptomatic PAD . Clinical endpoint analyzed subject enrol , regardless whether trial treatment administer successfully complete desired duration . A subject consider enrolled trial he/she randomize one treatment arm study . All endpoint subject-based unless otherwise specify . The primary endpoint subject-based long 12-month end study treatment endpoint first occurrence index limb arterial occlusion , surgical intervention , endovascular intervention , amputation affect limb ( primary patency limb salvage ) , MI , ischemic stroke death ( survival ) . The secondary endpoint subject-based longer 12 month end study treatment endpoint include : ( ) first occurrence individual component primary endpoint , ( b ) first occurrence follow follow-up : cardiovascular death , MI , ischemic stroke , amputation ankle ( c ) severe bleed define accord Global Utilization Streptokinase Tissue plasminogen activator Occluded coronary artery ( GUSTO ) classification . The tertiary endpoint base longer 12-month end study moderate bleeding accord GUSTO classification .</detailed_description>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<criteria>General : Signed informed consent At least 18 year old Documented symptomatic iliac , femoropopliteal ( FP ) belowthe knee artery ( BTK ) atherosclerotic disease ( Rutherford/Becker category 2 , 3 ≥4 ) Undergone clinically indicate uncomplicated endovascular intervention one location iliac , femoropopliteal belowthe knee artery Estimated survival ≥1 year judgment primary operator Preindex procedure use ASA , clopidogrel dose Angiographic : De novo restenotic lesion common and/or external iliac artery , superficial femoral artery ( SFA ) , popliteal artery , tibioperoneal ( TP ) trunk , anterior tibial ( AT ) artery , peroneal artery ( PA ) posterior tibial ( PT ) artery ( applies target lesion multiple ) Subjects multiple planned procedure enrol completion last planned procedure . General : Complicated qualify procedure ( perforation , flow limit dissection , distal embolization require reintervention , need repeat endovascular , surgical revascularization , amputation blood transfusion prior hospital discharge follow index procedure Extended hospital stay &gt; 7 day follow index procedure Allergy aspirin clopidogrel Life expectancy le 12 month due medical comorbid condition ( ) could limit subject 's ability participate trial , limit subject 's compliance followup requirement , impact scientific integrity trial Known hypersensitivity contraindication contrast dye , opinion investigator , adequately premedicated . Intolerance antiplatelet , anticoagulant , thrombolytic medication Platelet count &lt; 90,000 mm3 &gt; 600,000 mm3 Serum creatinine &gt; 2.5 mg/dL Dialysisdependent end stage renal disease Pregnancy Current participation another drug device trial require interruption dualantiplatelet therapy aspirin clopidogrel duration study Planned surgery , endovascular nonvascular cardiac procedure Concurrent warfarin chronic oral anticoagulant therapy Contraindication ( ) use AT ( history intracerebral bleed , presence intracerebral mass , recent &lt; 6 week gastrointestinal bleed , blood transfusion within last 6 week , trauma require surgery blood transfusion within last 4 week surgical procedure within last 4 week . Angiographic : Endovascular intervention iliac , femoropopliteal BTK artery bypass graft Persistent , intraluminal thrombus propose target lesion completion index procedure Perforated vessel evidence extravasation contrast medium Vascular graft , aneurysm postsurgical stenosis target vessel</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>peripheral arterial disease , antiplatelet therapy</keyword>
</DOC>